• Cynthia Morris, Zachary D Prudowsky, Vilaas Shetty, Thomas Geller, Samer K Elbabaa, Miguel Guzman, and Mohamed S AbdelBaki.
• Department of Child Neurology, St. Louis University School of Medicine, St. Louis, Missouri.
• World Neurosurg. 2017 Nov 1; 107: 1045.e9-1045.e16.

BackgroundRosette-forming glioneuronal tumor (RGNT) of the fourth ventricle is a rare World Health Organization (WHO) grade I neoplasm. Gross total resection (GTR) is the treatment of choice, and there is no firm evidence supporting other treatment options when GTR is not feasible.Case DescriptionWe report a 6-year-old boy who, following an initial subtotal resection of a fourth ventricular RGNT, received an individualized chemotherapy protocol with vincristine, etoposide, and carboplatin for 3 cycles. The tumor was stable for 2 years after the completion of chemotherapy but then began to progress, at which point GTR was successfully performed. In addition, we completed a comprehensive literature review of RGNT cases. To date, a total of 104 cases have been reported, 33 of which are pediatric cases. Recurrence has been reported in only 7 cases of all ages (4 in the pediatric population). Radiotherapy has been used in several cases, but adjuvant chemotherapy has been reported only once following a recurrence.ConclusionsWe report a case of chemotherapy administration as a first-line treatment for a subtotally resected RGNT. Chemotherapy may be considered as an adjuvant therapy option for RGNT when GTR cannot be achieved. Furthermore, increased incidence of recurrence in the pediatric population may suggest that the tumor biology of RGNT in children differs from that in adults.Copyright © 2017 Elsevier Inc. All rights reserved.

18 keywords...

hide…